GlassScriptPhysician profile
Laren D Tan
NPI 1821230467
$187,217.93
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140K · 2020: $44K · 2021: $3,000 · 2022: $166.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $100,451.66 | 2019-2022 | |
| Genzyme Corporation | $34,585.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24,141.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,687.14 | 2019-2020 | |
| Boston Scientific Corporation | $5,154.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $4,271.22 | 2019 | |
| Glaxosmithkline, LLC. | $3,731.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $131.99 | 2019 | |
| Grifols USA, LLC | $62.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laren Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.